“We intend to quicken the pace of cure research by supporting a collaborative community of leading HIV researchers in one cohesive enterprise.” - Kevin Robert Frost, amfAR Chief Executive Officer
An Exciting New Research Collaboration
Launched on the eve of World AIDS Day 2015, the amfAR Institute for HIV Cure Research is the centerpiece of our $100 million investment strategy aimed at developing the scientific basis of a cure by the end of 2020.
Established with a five-year $20 million grant to the University of California, San Francisco, the Institute brings together many of the finest minds and most experienced researchers working in the field today.
Under the direction of renowned AIDS researcher Dr. Paul Volberding, teams of investigators are working collaboratively to address the scientific challenges that stand in the way of a cure.
Institute Director Dr. Paul Volberding
What’s New at the Institute?
HIV Reservoirs in the Blood and Gut Respond Differently to Virus Activators
The Past, Present, and Future of HIV Reservoir Cells
Launching an HIV Trial in the Time of COVID-19
Pioneering Clinical Trial Gets Underway
When Treatment Stops, Why Can’t the Immune System Suppress HIV?
The Reservoir, in Ultra High Res
Does ART Adequately Reach Tissue Reservoirs of HIV?
Probing the Provirus
Uncovering Novel Anti-HIV Factors
About the amfAR Institute
amfAR Establishes San Francisco-Based Institute for HIV Cure Research
amfAR Institute for HIV Cure Research: The Work Ahead
Principal Investigators and Collaborating Institutions
Our Moonshot by amfAR CEO Kevin Robert Frost
amfAR’s Countdown to a Cure for AIDS Initiative
amfAR Announces $100 Million Investment Strategy Aimed at Curing HIV